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By Nancy West
During the past decade, growth in the 
biotechnology industry has exploded with U.S. 
revenues increasing nearly fivefold, from $8 
billion in 1992 to $39.2 billion in 2003. During 
roughly the same period, research and develop-
ment spending in the U.S. biotech industry more 
than doubled from $7 billion to $17.9 billion, 
while the number of biotechnology patents 
granted per year more than tripled from about 
2,500 in 1992 to nearly 7,800 in 2002. Employ-
ment in the industry soared from 103,000 in 
1994 to more than 198,000 in 2003. 
Attracted by a wide range of opportunities, a 
growing number of Penn Veterinary Medicine 
alumni are finding rewarding careers in 
biotechnology where they enjoy the advantages 
of a resource-rich industry and entrepreneurial 
spirit as well as the excitement of research and 
discovery that has the potential to enhance 
human and animal health.
Following are the stories of three Penn alumni 
who have found success and fulfillment in the 
biotechnology field. 
Douglas J. Ringler, C’79, V’83: 
A Promising Therapy for Type I Diabetes
During his teenage years in upstate New York, 
Doug Ringler, C’79, V’83, worked at a mixed 
veterinary practice where a large number of the 
patients were dairy cows. He loved the experi-
ence and had every intention of joining the 
practice after finishing veterinary school. Instead, 
he joined a small-animal practice in Boston and, 
after just a few months, made a discovery that 
was surprising even to him. Although he enjoyed 
veterinary practice, he wanted something more. 
“I quickly found myself looking for the next 
challenge in my career,” Dr. Ringler recalls. 
“I wanted to work on new goals that would 
complement what I had already experienced, so I 
decided to return to academia.” 
After completing a residency and a post-doc-
toral fellowship in pathology at Harvard Medical 
School, Dr. Ringler joined the school’s medical 
faculty. During his 10 years at Harvard, he ulti-
mately served as associate professor of pathology 
and chairman of the Division of Comparative 
Pathology, and directed a pathology lab of 20 
pursuing research in inflammatory mechanisms. 
In 1993, Dr. Ringler decided it was time to 
move on to the next phase of his career—trans-
lating basic research findings into the clinical 
venue. That year, he ventured into the biotech 
industry as a founding scientist and executive 
officer of LeukoSite, Inc., a biotech company 
focused on the development of therapies to alter 
immunological responses. 
Five years later, the successful company was 
sold to Millennium Pharmaceuticals, which 
marketed two products based on the research 
and development done by Dr. Ringler and his 
colleagues, including Campath®, a monoclonal 
antibody for refractory chronic lymphocytic 
leukemia, and Velcade®, a treatment for multiple 
myeloma. Another biotech firm, Genzyme, 
acquired the rights to and is now developing 
Campath® as a treatment for multiple sclerosis. 
Today, Dr. Ringler is president and CEO 
of TolerRx, a biopharmaceutical company he 
co-founded in 2000 to focus on the discovery, 
development, and commercialization of novel 
therapies to treat patients with immunological 
diseases, including Type I diabetes, psoriasis, and 
hemophilia A. 
“We are now moving toward Phase III testing 
in humans with a monoclonal antibody that we 
believe can very significantly change the disease 
course in Type I diabetics,” says Dr. Ringler, 
noting that an article will soon appear in the 
New England Journal of Medicine about these 
unprecedented findings. 
“Knowing that your efforts are benefiting 
others is tremendously rewarding,” he says. “We 
expect this product to modulate the disease 
course in children, young adults, and adults with 
Type I diabetes. We hope to significantly reduce 
the side effects from the disease that are largely 
vascular related.”
TolerRx is also running Phase I clinical 
trials on the same product for the treatment of 
psoriasis, and expects to begin Phase I trials this 
year with a second product designed to induce 
tolerance in transplantation, autoimmune 
diseases such as lupus, and clinical situations 
where the immune system attacks therapeutic 
proteins or biologic drugs, such as Factor VIII in 
hemophilia A. 
“Biotech is a terrific career path for a 
veterinarian,” says Dr. Ringler. “Very few careers 
give you the opportunity to participate in drug 
discovery and development at all levels of the 
process. You can start at the bench and take it 
all the way to the patient’s bedside, which is 
tremendously rewarding. Veterinary training, 
especially at Penn, gives you a unique perspective 
that is very valuable in this process.” 
Mark J. Pykett, V’91,PhD’94, MBA: 
Developing CNS Diagnostics and Therapeutics 
The research lab was always the end goal 
for Mark Pykett, V’91, PhD’94, MBA. Now 
president and chief operating officer of Boston 
Life Sciences, Inc., a biotechnology company 
focused on research and clinical development of 
diagnostic and therapeutic products for central 
nervous system (CNS) disorders, Dr. Pykett 
says that he was motivated to attend veterinary 
school for his training because he believed it 
would give him the best, broad-based training. 
He was not disappointed.
“I chose Penn because of the Veterinary Medi-
cal Scientist Training Program,” he says. “I liked 
the fact that this combined VMD/PhD degree 
program was well integrated between the vet 
school and the graduate research environment.”
Dr. Pykett also believed that the diversity of 
species, conditions and diseases encountered in 
veterinary school would provide him with better 
interdisciplinary approaches, better translational 
capabilities, and a better ability to think outside 
the box and extrapolate findings between species. 
After completing the program and a 
post-doctoral fellowship at Penn, he moved on 
to Harvard School of Public Health, where he 
completed a second post-doctoral fellowship on 
the molecular basis of cancer and then held an 
adjunct faculty position for five years. 
Dr. Pykett expected to remain in an academic 
career, but switched gears when he became inter-
ested in Boston’s hot biotechnology industry. 
“While at Harvard, I had the opportunity to see 
the entrepreneurial side of medical research,” he 
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(continued from page 29) to veterinarians who are interested in research,” 
he notes. “In smaller biotech companies, you 
have the opportunity to be entrepreneurial and 
innovative and play a leadership role very early 
in your career. For me, the incentives, flexibility, 
and autonomy in the biotech industry, combined 
with the opportunity to do innovative work that 
moves at a rapid pace, have brought a tremen-
dous amount of career satisfaction.”
Kenneth L. Mohn, V’88, PhD’91: 
Research and Discovery in Large Pharma
As a boy growing up at the edge of 
the Pine Barrens in Tom’s River, N.J., 
Ken Mohn, V’88, PhD’91, spent a lot of time 
in the woods catching snakes, lizards, and other 
creatures, observing them for a while, then 
letting them go free. “I always loved animals 
and related well to them,” recalls Dr. Mohn. 
“Everyone said, ‘You should be a veterinarian.’ 
But I wanted to be a Marlin Perkins or Jacques 
Costeau. That seemed more exciting.”
Nevertheless, Dr. Mohn decided to pursue a 
veterinary career. “I grew up in a strong Christian 
home and I believed that was God’s direction for 
my life,” he says. While pursuing an undergradu-
ate degree in animal science at Rutgers University, 
he had the opportunity to work on a highly 
successful honors research project. That experi-
ence ignited his interest in a career that would 
combine his love of animals and research. 
“In the midst of that project, I was apply-
ing to veterinary schools,” explains Dr. Mohn. 
“When I saw the Veterinary Medical Scientist 
Training Program in Penn’s brochure, I knew 
that was the place for me.”
While in school, he completed a lab animal 
medicine rotation at Merck. “I was intrigued by 
the pharmaceutical industry and the oppor-
tunity to do practically oriented research in a 
well-funded organization,” he states. In 1992, he 
joined Merck’s Basic Animal Science Research 
group, which focuses on the development of 
novel veterinary pharma products. 
Serving first as a research fellow and then 
research veterinarian during the past 13 years, 
Dr. Mohn has worked on a wide range of proj-
ects, from allergy treatments for dogs and cats 
to feline dental products to growth promotants 
for pigs and cattle to poultry products, and even 
some human-health products. 
Currently, he is in charge of a parasitology 
laboratory looking for a broad spectrum anti-
recalls. “At about the same time, I learned about 
a technology that I thought had interesting 
prospects as the seed for a biotech company.”
Together with the inventor of the technol-
ogy and a colleague from Penn, Dr. Pykett 
co-founded and served as president and CEO 
for Cytomatrix, a startup company that focused 
on developing cell therapeutics. Later, he served 
as president of Cordlife, a cell therapy biotech 
company that acquired his successful company, 
and of CyGenics, a global adult stem cell and cell 
therapy biotech company. 
Since 2004, he has overseen operations at 
Boston Life Sciences, Inc. (BLSI). He also serves 
on the board of directors of several public and 
private biotech companies. The current lead 
product in the BLSI pipeline is ALTROPANE®, a 
diagnostic imaging agent for the early diagnosis 
of Parkinson’s disease, which is currently in Sec-
ond Phase III clinical trials. “Our goal is to show 
that ALTROPANE® will improve the medical 
community’s ability to differentiate Parkinson’s 
disease from non-Parkinsonian movement 
disorders,” says Dr. Pykett. ALTROPANE® is also 
in Phase II clinical trials for use in objectively 
diagnosing attention deficit hyperactivity 
disorder (ADHD). Other products in the 
pipeline include a nerve growth factor for the 
treatment of stroke and spinal cord injury and a 
novel DAT (dopamine transporter) blocker for 
the treatment of Parkinson’s disease. 
“The challenge of bringing innovations 
through the entire development and com-
mercialization process that, hopefully, will lead 
to a product that can enhance the lives of many 
people is extremely rewarding,” states Dr. Pykett. 
“The biotech industry offers a host of benefits 
parasitic drug with the potential to take the place 
of ivermectin.
Dr. Mohn holds a patent for a product 
developed to treat feline dental resorptive 
lesions, which he is hopeful will reach the 
marketplace. He also takes pride in his contribu-
tions to a reproductive control project in which 
his veterinary training played a key role. “My 
observations evolved into an exciting program to 
develop a reproductive control vaccine targeted 
primarily to the pork industry,” he says.
Dr. Mohn enjoys the fact that, in addition to 
research, he is also responsible for the health of 
horses, cattle, swine, chickens, and sheep residing 
at Merck’s 200-acre research farm where he has 
worked for the past five years. “I really missed 
the hands-on contact with animals when I was 
just working in the lab,” he relates. “Now I have 
the opportunity to treat a horse or a cow and 
to run some in vivo studies while maintaining a 
productive in vitro laboratory. . . it’s the best of 
both worlds.”
Dr. Mohn has found his veterinary train-
ing invaluable throughout his career. “I’ve led 
many multidisciplinary project teams because 
of my diverse training,” he notes. “It helps 
tremendously in understanding the process for 
which we’re trying to develop a therapy and for 
developing valid animal models.” 
The rewards of research work at a large 
pharma company are enormous, he says. “In 
addition to significant financial benefits, you 
have huge opportunities to be creative and apply 
your veterinary skills to pursue a goal that may 
have a very significant impact on animal health 
worldwide and contribute to human health as 
well. It’s exciting to think that your discoveries 
may ultimately change the way people practice 
medicine.” ■
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